0000950170-24-080921.txt : 20240702
0000950170-24-080921.hdr.sgml : 20240702
20240702185516
ACCESSION NUMBER: 0000950170-24-080921
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240628
FILED AS OF DATE: 20240702
DATE AS OF CHANGE: 20240702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Young Jonathan
CENTRAL INDEX KEY: 0001779805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 241097689
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-06-28
0001744659
Akero Therapeutics, Inc.
AKRO
0001779805
Young Jonathan
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94941
false
true
false
false
Chief Operating Officer
true
Common Stock
2024-06-28
5
A
false
1064
19.941
A
251854
D
Common Stock
2024-07-01
4
S
false
5000
23.404
D
246854
D
Common Stock
20000
I
By EA Irrevocable Trust
Common Stock
20000
I
By CM Irrevocable Trust
Common Stock
20000
I
By JL Irrevocable Trust
Dr. Young is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024.
These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 27, 2023, previously adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.185 to $23.680, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 5.
/s/ Jonathan Young
2024-07-02